Mariella G. Filbin, MD, PhD, is a Pediatric Neurooncologist and Principal Investigator at Dana-Farber Cancer Institute and Boston Children’s Hospital, and an Assistant Professor in Pediatrics at Harvard Medical School. Her research focuses on pediatric brain tumors, particularly the high-grade gliomas and malignant embryonal brain tumors that are in greatest need of therapeutic improvements. In her studies, she is combining single-cell genetics and transcriptomics with gene editing, epigenetic, stem cell, and pharmacologic methods to identify networks underlying tumorigenesis, with the goal of establishing new druggable targets.
Dr. Filbin has been recognized with many honors and awards, including the NIH director's New Innovator award, the Distinguished Scientist Award from the Sontag Foundation, career awards from the Burroughs Wellcome Fund, Alex’s Lemonade Stand Foundation, National Cancer Institute, Broad Institute of MIT and Harvard, and Austrian Academy of Science. She also received teaching awards from Harvard Medical School.
She is the Co-director of the Pediatric Neuro-Oncology Program at Dana-Farber Cancer Institute and Boston Children’s Hospital, Co-director of the Brain Tumor Program at Boston Children's Hospital, Co-leader of the Academy of Basic and Translational Investigation at Boston Children’s Hospital, Co-director of the Count Me In Brain Tumor Project, and also serves on the Scientific Committee of the Pacific Neuro-Oncology Consortium and the Children’s Oncology Group High Grade Glioma working group.
Dr. Filbin completed her initial Doctor of Medicine and Doctor of Philosophy in Vienna, Austria, before completing her pediatrics residency at Boston Children’s Hospital and her subspecialty fellowship training in pediatric hematology/oncology at Dana-Farber/Boston Children’s. She trained in the laboratories of Rosalind Segal, MD, PhD, at Dana-Farber; Todd Golub, MD, at Dana-Farber and the Broad Institute; and Mario Suva, MD, PhD, at Massachusetts General Hospital. Dr. Filbin established her own laboratory at Dana-Farber Cancer Institute in 2018.